文献速递肺栓塞与肺血管病

肺动脉高压患者6分钟步行距离的最小临床重要差异

Minimal Clinically Important Difference in the 6-minute-walk Distance for Patients with Pulmonary Arterial Hypertension.
PubMed 文献 · Am J Respir Crit Care Med · 2023-01-01

本研究通过荟萃分析8项提交至美国食品药品监督管理局的肺动脉高压随机临床试验的个体参与者数据,推导6分钟步行距离的最小临床重要差异,并用肺动脉高压协会登记处进行外部验证。推导样本2404例、验证样本537例成人肺动脉高压患者。推导样本的最小临床重要差异为33米(95%CI 27-38),验证样本为36米(95%CI 29-43),且不因年龄、性别、种族、病因、体重指数、背景治疗或WHO功能分级而异。

要点

  • 成人肺动脉高压患者6分钟步行距离的最小临床重要差异约为33米。
  • 该阈值在外部验证队列中几乎一致(36米),支持其稳健性。
  • 最小临床重要差异不受年龄、性别、种族、病因、BMI、背景治疗或WHO功能分级影响。

核心结论

  • 成人肺动脉高压患者6分钟步行距离的最小临床重要差异约为33米。

研究设计与样本

  • 研究采用荟萃分析,纳入8项提交至美国食品药品监督管理局的肺动脉高压治疗随机临床试验的个体参与者数据,推导最小临床重要差异。
  • 推导样本为2404例成人肺动脉高压患者,验证样本为537例来自肺动脉高压协会登记处的成人患者。
  • 以医学结局研究简表生理功能成分评分的变化作为锚定指标。

主要发现

  • 推导样本中6分钟步行距离的最小临床重要差异为33米(95%CI 27-38)。
  • 验证样本中6分钟步行距离的最小临床重要差异为36米(95%CI 29-43)。
  • 最小临床重要差异不因年龄、性别、种族、肺动脉高压病因、体重指数、背景治疗使用或WHO功能分级而不同。
  • 推导样本平均年龄50.5±15.2岁,女性1849例(77%),验证样本特征相似。

关键数值与推荐

  • 6分钟步行距离变化锚定于医学结局研究简表生理功能成分评分的变化。
  • 推导样本最小临床重要差异33米(95%CI 27-38),验证样本36米(95%CI 29-43)。

临床怎么用

  • 可将约33米的6分钟步行距离变化作为成人肺动脉高压患者临床有意义的阈值。
  • 该阈值可用于肺动脉高压治疗临床试验的设计。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Rationale: The 6-minute-walk distance (6MWD) is an important clinical and research metric in pulmonary arterial hypertension (PAH); however, there is no consensus about what minimal change in 6MWD is clinically significant. Objectives: We aimed to determine the minimal clinically important difference in the 6MWD. Methods: We performed a meta-analysis using individual participant data from eight randomized clinical trials of therapy for PAH submitted to the U.S. Food and Drug Administration to derive minimal clinically important differences in the 6MWD. The estimates were externally validated using the Pulmonary Hypertension Association Registry. We anchored the change in 6MWD to the change in the Medical Outcomes Survey Short Form physical component score. Measurements and Main Results: The derivation (clinical trial) and validation (Pulmonary Hypertension Association Registry) samples were comprised of 2,404 and 537 adult patients with PAH, respectively. The mean ± standard deviation age of the derivation sample was 50.5 ± 15.2 years, and 1,849 (77%) were female, similar to the validation sample. The minimal clinically important difference in the derivation sample was 33 meters (95% confidence interval, 27-38), which was almost identical to that in the validation sample (36 m [95% confidence interval, 29-43]). The minimal clinically important difference did not differ by age, sex, race, pulmonary hypertension etiology, body mass index, use of background therapy, or World Health Organization functional class. Conclusions: We estimated a 6MWD minimal clinically important difference of approximately 33 meters for adults with PAH. Our findings can be applied to the design of clinical trials of therapies for PAH.

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

引用

  1. Moutchia J, McClelland RL, Al-Naamani N, et al. Minimal Clinically Important Difference in the 6-minute-walk Distance for Patients with Pulmonary Arterial Hypertension. Am J Respir Crit Care Med. 2023. PMID: 36629737. doi:10.1164/rccm.202208-1547OC

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。